<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763672</url>
  </required_header>
  <id_info>
    <org_study_id>P051060</org_study_id>
    <nct_id>NCT00763672</nct_id>
  </id_info>
  <brief_title>MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study</brief_title>
  <acronym>MOMA</acronym>
  <official_title>Impact of a Single Second-trimester Plasma sFlt-1 and/or Urinary PlGF Assay on Maternofetal Morbidity/Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether close monitoring of patients with a high
      sFlt1 plasma level between 25 and 28 weeks of gestation (i.e. at high risk of subsequent
      preeclampsia) improves maternal and fetal outcomes. The investigator hypothesize that 1/
      early screening for preeclampsia by plasmatic sFlt1 will reduce maternal and fetal mortality
      and morbidity and 2/ a simple urinary PlGF screening will be effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will measure plasmatic sFlt-1 level between 25 and 28 weeks of gestation and flow velocity
      of uterine arteries by Doppler (22 - 26 weeks of gestation) in primipara. Patients will be
      stratified according to the results of the uterine artery Doppler measurement, and then
      randomized in two groups A and B. In group A, sFlt-1 concentration will be communicated to
      the obstetrician (+ or -): the threshold of abnormally high plasmatic concentration of sFlt-1
      is 957 ng/mL. In patients with a high plasmatic concentration of sFlt-1 (+), the pregnancy
      will be closely monitored including repeated clinical, biological, and ultrasound
      examinations. Patients with sFlt-1 plasmatic concentration below 957 ng/mL (-) will be
      routinely followed-up.In group B, the result of sFlt-1 measurement will not be communicated
      and the pregnancy will be routinely monitored.Abnormal Doppler recordings in either group
      will result in a close monitoring as per our usual local practice. Urinary PlGF (expressed as
      a ratio PlGF/creatininemia) will also be measured and the results will be analyzed at the end
      of the study. Beside sFlt-1, we will store the plasmatic samples to measure other biomarkers
      that could be relevant in the future (no DNA analysis will be done without a new patient
      consent).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the maternal and fetal morbimortality score</measure>
    <time_frame>During the pregnancy and the 3 first month of the child</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child status</measure>
    <time_frame>at 3 months post-delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay during pregnancy and post-partum periods</measure>
    <time_frame>during pregnancy and post-partum periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive value for vascula-renal disease of urinary PlGF as compared with plasmatic sFlt-1.</measure>
    <time_frame>between 25 and 28 weeks of gestation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1040</enrollment>
  <condition>Pregnancy</condition>
  <condition>Primiparity</condition>
  <condition>Hypertension</condition>
  <condition>Preeclampsia</condition>
  <condition>Intrauterine Growth Retardation</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sFlt-1 status known</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>sFlt-1 status unknown</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transmission of sFlt-1 results to the investigator</intervention_name>
    <description>Transmission of sFlt-1 results by the laboratory to the investigator</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Transmission of sFlt-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No transmission of the sFlt-1 results to the investigator</intervention_name>
    <description>The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>No transmission of the sFlt-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant womenAge ≥ 18 years

          -  Followed in our center before the 28th week of gestation

          -  Under social security coverage

          -  Signed informed consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Followed in our center after the 28th week of gestation

          -  No social security coverage

          -  Refusal to be included
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadia BERKANE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gynecology Obstetrics and Reproductive Medicine, Hôpital Tenon, AP-HP, UPMC</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005 Feb 26-Mar 4;365(9461):785-99. Review.</citation>
    <PMID>15733721</PMID>
  </reference>
  <reference>
    <citation>Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology. 2004 Nov;145(11):4838-45. Epub 2004 Jul 29.</citation>
    <PMID>15284201</PMID>
  </reference>
  <reference>
    <citation>Familoni OB, Adefuye PO, Olunuga TO. Pattern and factors affecting the outcome of pregnancy in hypertensive patients. J Natl Med Assoc. 2004 Dec;96(12):1626-31.</citation>
    <PMID>15622693</PMID>
  </reference>
  <reference>
    <citation>Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 Mar;111(5):649-58.</citation>
    <PMID>12618519</PMID>
  </reference>
  <reference>
    <citation>Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003 Apr 11;278(15):12605-8. Epub 2003 Jan 21.</citation>
    <PMID>12538598</PMID>
  </reference>
  <reference>
    <citation>Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest. 2003 Mar;111(5):600-2.</citation>
    <PMID>12618513</PMID>
  </reference>
  <reference>
    <citation>Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab. 2003 May;88(5):2348-51.</citation>
    <PMID>12727995</PMID>
  </reference>
  <reference>
    <citation>Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008 Jan;21(1):9-23. doi: 10.1080/14767050701830480.</citation>
    <PMID>18175241</PMID>
  </reference>
  <reference>
    <citation>Stepan H, Geide A, Faber R. Soluble fms-like tyrosine kinase 1. N Engl J Med. 2004 Nov 18;351(21):2241-2.</citation>
    <PMID>15548791</PMID>
  </reference>
  <reference>
    <citation>Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12;350(7):672-83. Epub 2004 Feb 5.</citation>
    <PMID>14764923</PMID>
  </reference>
  <reference>
    <citation>Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004 Sep;50(9):1702-3.</citation>
    <PMID>15331514</PMID>
  </reference>
  <reference>
    <citation>Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Urinary placental growth factor and risk of preeclampsia. JAMA. 2005 Jan 5;293(1):77-85.</citation>
    <PMID>15632339</PMID>
  </reference>
  <reference>
    <citation>Berkane N, Hertig A, Rondeau E, Uzan S. Hypertensive disorders of pregnancy: future perspectives. A French point of view. Curr Opin Obstet Gynecol. 2008 Apr;20(2):107-9. doi: 10.1097/GCO.0b013e3282f73391. Review.</citation>
    <PMID>18388807</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2008</study_first_posted>
  <last_update_submitted>March 26, 2013</last_update_submitted>
  <last_update_submitted_qc>March 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Intra uterine growth retardation</keyword>
  <keyword>Antiangiogenic factor</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

